HEALEY ALS Platform Trial - Master Protocol

- Enrolling May 2026!

For more information, please visit this website:  NCT04297683

https://www.massgeneral.org/neurology/als/research/platform-trial

To enroll in this study at USF please contact Sruthi Kommi Reddy at (813) 974-9413

FA – ALCAR – Currently Enrolling

The purpose of this study is to learn how treatment with acetyl-L-carnitine (ALCAR) will affect the hearts of patients with Friedreich's Ataxia as well as how it may affect other symptoms of Friedreich's Ataxia such as difficulties with balance, walking, or upper arm function.

 For more information please visit the website at https://clinicaltrials.gov/ct2/show/NCT01921868

To enroll in this study at USF Health  please contact:
Lucrectia Campbell or Paige Graham
(813) 974-5909

FA – Reata – Currently Enrolling

This 2-part study will evaluate the efficacy, safety, and pharmacodynamics of omaveloxolone (RTA 408) in the treatment of patients with Friedreich's ataxia.

For more information please visit the website at: https://clinicaltrials.gov/ct2/show/NCT02255435

To enroll in this study at USF Health please contact:
Lucrectia Campbell or Paige Graham
(813) 974-5909

FA – COMS – Currently Enrolling

This is a long-term study of the natural progression of disease in Friedreich’s Ataxia (FA)

To enroll in this study at USF Health  please contact:
Lucretia Campbell or Paige Graham
(813) 974-5909

Retrotope RTMOTION – Ongoing Not Enrolling

This is a study of a wearable gait device detecting movement in 3D in patients with movement disorders.

To enroll in this study at USF Health please contact:
Lecretia Campbell or Paige Graham
(813) 974-5909

SCA - IVIG 2014 – Currently Enrolling

The purpose of this study is to learn how Intravenous Immune Globulin (IVIG) will affect Spinocerebellar Ataxia (SCA) symptoms and how it will affect motor and nervous system function in participants Subtypes of SCA to be examined will include SCA types 1, 2, 3, 6, 10 and 11.

For more information please visit the website at:

https://clinicaltrials.gov/ct2/show/NCT02287064

To enroll in this study at USF Health please contact:
Lucretia Campbell or Paige Graham
(813) 974-5909

FA - Gait and Balance – Currently Enrolling

The purpose of this study is to assess gait and balance changes in Friedreich’s ataxia patients over the course of 12 months and correlate these changes to clinical measures of ataxia.

To enroll in this study at USF Health please contact:
Lucretia Campbell or Paige Graham
(813) 974-5909

PSP - BMS CN002-003 – Currently Enrolling

The goal of this study is to evaluate the safety and tolerability of multiple doses of BMS-986168 in patients with PSP.

For more information please visit the website at:

https://clinicaltrials.gov/ct2/show/NCT02460094

To enroll in this study at USF Health please contact:
Lucretia Campbell or Paige Graham
(813) 974-5909

SCA - BHV4157-201 (Biohaven) – Start-up/Pending

The purpose of this study is to compare the efficacy of BHV-4157 versus placebo on ataxia symptoms in subjects with spinocerebellar ataxia (SCA).

For more information please visit the website at:

https://clinicaltrials.gov/ct2/show/NCT02460094

To enroll in this study at USF Health please contact:
Lucretia Campbell or Paige Graham
(813) 974-5909

PSP - Abbvie M15-562 – Start-uo/Pending

The purpose of this study is to assess the efficacy and long term safety and tolerability of ABBV-8E12 for up to 52 weeks in subjects with progressive supranuclear palsy (PSP).

To enroll in this study at USF Health please contact: Lucretia Campbell or Paige Graham (813) 974-5909

CVL-865-SZ-001 (REALIZE) Currently Enrolling

Research study testing an experimental drug called CVL-865 for adults (18 to 75 years old) with focal epilepsy who still experience seizures despite taking medication. The trial aims to determine if adding CVL-865 to current anti-seizure medications can improve seizure control while assessing safety.

For more information on this study please visit the website: https://clinicaltrials.gov/study/NCT04244175?term=CVL-865-SZ-001&rank=1

Realize Trial

For additional information about potential enrollment please contact:
Marina Azevedo: (813) 230-2323
Ana Omura: (813) 259-8524

EQU2-02 (EQUILIBRIUM) Currently Enrolling

Research study investigating an experimental drug called EQU-001 for adults (18 to 65 years old) with focal epilepsy who continue to have seizures despite medication. The trial aims to evaluate if adding EQU-001 to current anti-seizure medications can improve seizure control while ensuring safety.

For more information on this study please visit the website: https://clinicaltrials.gov/study/NCT05473442?term=EQU-202%20EQUILIBRE&rank=1

Equilibre Biopharmaceuticals Trial

For additional information about potential enrollment please contact:
Marina Azevedo: (813) 230-2323
Ana Omura: (813) 259-8524

GWEP19022 (ILLUMINATE) Currently Enrolling

Safety study for individuals with Lennox-Gastaut Syndrome, Dravet Syndrome, or Tuberous Sclerosis Complex who receive or will start Epidiolex therapy. The trial focuses on evaluating the safety of Epidiolex and monitoring any associated risks.

For more information on this study please visit the website: https://clinicaltrials.gov/study/NCT05044819?term=GWEP19022&rank=1

For additional information about potential enrollment please contact:
Marina Azevedo: (813) 230-2323
Ana Omura: (813) 259-8524

LP352-201 (LONGBOARD) Currently Enrolling

Research study testing an experimental drug called LP352 for patients (12 to 65 years old) with Developmental and epileptic encephalopathy (DEE) such as Lennox-Gastaut Syndrome, Dravet Syndrome, and Tuberous Sclerosis Complex. The trial aims to determine if adding LP352 to current anti-seizure medications can improve seizure control

For more information on this study please visit the website: https://clinicaltrials.gov/study/NCT05364021?term=LP352-201%20&rank=2

For additional information about potential enrollment please contact:
Marina Azevedo: (813) 230-2323
Ana Omura: (813) 259-8524

YKP509C003 (CARISBAMATE) Currently Enrolling

Research study investigating an experimental drug called YKP509 for individuals (4 to 55 years old) diagnosed with Lennox-Gastaut Syndrome and experiencing drop seizures. The trial aims to evaluate if adding YKP509 to current anti-seizure medications can effectively improve drop seizure control.

For more information on this study please visit the website: https://clinicaltrials.gov/study/NCT05219617?term=YKP509C003&rank=1

For additional information about potential enrollment please contact:
Marina Azevedo: 813) 230-2323
Ana Omura: (813) 259-8524

NP100016 (NAUTILUS Trial) Currently Enrolling

Research study assessing the effectiveness of a device called Responsive Neurostimulation System (RNS)* for individuals (12 years and older) with idiopathic generalized epilepsy (IGE) who experience generalized tonic-clonic seizures (GTCs). The trial evaluates if the RNS system, in addition to current anti-seizure medications, can improve seizure control. *The RNS system is currently FDA approved for patients diagnosed with focal epilepsy (when seizures come from one side of the brain).

For more information on this study please visit the website: https://clinicaltrials.gov/study/NCT05147571?term=nautilus&rank=1

NAUTILUS Epilepsy Study

For additional information about potential enrollment please contact:
Marina Azevedo: (813) 230-2323
Ana Omura: (813) 259-8524

YKP3089C025 (Xcopri Trial) Currently Enrolling

Research study investigating a drug called Cenobamate (Xcopri) for adults (18 years and older) diagnosed with idiopathic generalized epilepsy (IGE) and experiencing primary generalized tonic-clonic seizures (GTCs). The trial aims to determine if adding Cenobamate to current anti-seizure medications can improve seizure control.

For more information on this study please visit the website: https://clinicaltrials.gov/study/NCT03678753?term=YKP3089C025&rank=2

For additional information about potential enrollment please contact:
Marina Azevedo: (813) 230-2323
Ana Omura: (813) 259-8524

1024SE3003 (RAISE Trial) Currently Enrolling

Research study testing an experimental drug called Ganaxolone for patients (12 years and older) diagnosed with Status Epilepticus (SE), a prolonged seizure condition. The trial assesses whether administering Intravenous (IV) Ganaxolone can effectively terminate ongoing seizure activity in individuals with Status Epilepticus, while monitoring safety.

For more information on this study please visit the website: https://classic.clinicaltrials.gov/ct2/show/NCT04391569

Marinus Pharmaceuticals

For additional information about potential enrollment please contact:
Marina Azevedo: (813) 230-2323
Ana Omura: (813) 259-8524

EP0162 (STARS Trial) Currently Enrolling

The STARS (Stand Together Against pRolonged Seizures) Research Study is a clinical trial for a drug called Alprazolam, which is sometimes used to treat seizures. This study aims to determine if Alprazolam, administered via a Staccato Inhaler Device, will work to stop prolonged seizures that last more than 3 minutes.

For more information on this study please visit the website: https://clinicaltrials.gov/study/NCT05077904?term=EP0162%20STACCATO&rank=1

UCB STARS Trial

For additional information about potential enrollment please contact:
Marina Azevedo: (813) 230-2323
Ana Omura: (813) 259-8524

REMI-01-23 (REMI Trial) Currently Enrolling

A study for adults aged 18 to 70 years old who have a history of seizures, including epileptic, non-epileptic or unknown seizures. Participants in this study experience seizures and their healthcare provider has recommended an at-home electroencephalogram (EEG). This study aims to investigate whether an extended EEG duration (REMI) yields a higher number of detected events compared to a standard EEG.

For more information on this study please visit the website: https://clinicaltrials.gov/study/NCT05818930?term=remi%20epitel&rank=1

Epitel

For additional information about potential enrollment please contact:
Marina Azevedo: (813) 230-2323
Ana Omura: (813) 259-8524

STUDY005226 (NELLI Trial) Currently Enrolling

This is a research study of an experimental device called Nelli for individuals who have a history of seizures with a motor component, including epileptic, non-epileptic or unknown seizures. Participants in this study experience seizures that involve some form of body movement, and their healthcare provider has recommended an at-home electroencephalogram (EEG) to monitor their brain activity during these episodes. The purpose of this study is assess if the NELLI artificial intelligence device can correctly identify seizures.

For more information on this study please visit the website: https://www.neuroeventlabs.fi/

For additional information about potential enrollment please contact:
Marina Azevedo: (813) 230-2323
Ana Omura: (813) 259-8524

NOE-TGN-201

Libra

(Currently Enrolling)

A Phase II/III, Multicentre, 8-week Run-in Phase Followed by a 12-Week, Prospective, Parallel-group, Double-blind, Randomized Withdrawal, Placebo-controlled Study, with a 52-Week Open Label Extension, to Evaluate the Efficacy and Safety of Daily 1.5 to 3.5 mg Basimglurant in Patients with Pain Associated with Trigeminal Neuralgia with Suboptimal Response to their Current Anti-pain Therapy.

For more information please contact:

Allyssa Sawyer at (813) 396-2736

M21-307

Preclude

(Active - 
Not Currently Enrolling)

Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study of BOTOX (Botulinum Toxin Type A) for the Prevention of Migraine in Subjects with Episodic Migraine.

For more information please contact:

Allyssa Sawyer at (813) 396-2736

H8H-MC-LAHV

PIONEER-PEDS1

(Currently Enrolling)

A Randomized, Double-Blind, Placebo-Controlled Study of Lasmiditan for Acute Treatment of Migraine: PIONEER-PEDS1.

For more information please contact:

Justis Root at (813) 396-2282

H8H-MC-LAHW

PIONEER-PEDS2

(Currently Enrolling)

A Phase 3, 12-Month, Open-Label Study of Lasmiditan in Pediatric Patients with Migraine - PIONEER-PEDS2.

For more information please contact:

Justis Root at (813) 396-2282

I5Q-MC-CGAS

REBUILD-1

(Currently Enrolling)

A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Patients 6 to 17 Years of Age with Episodic Migraine – the REBUILD-1 Study.

For more information please contact:

Justis Root at (813) 396-2282

I5Q-MC-CGAT

REBUILD-2

(Currently Enrolling)

A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adolescent Patients 12 to 17 Years of Age with Chronic Migraine – the REBUILD-2 Study.

For more information please contact:

Justis Root at (813) 396-2282

3110-305-002

(Currently Enrolling)

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Single-attack Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura in Children and Adolescents (Ages 6-17).

For more information please contact:

Allyssa Sawyer at (813) 396-2736

3110-306-002

(Currently Enrolling)

A Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura in Children and Adolescents (Ages 6-17).

For more information please contact:

Allyssa Sawyer at (813) 396-2736

P255-501 “ROAR”

(Currently Enrolling)

A Randomized, Double-Blind, Placebo-Controlled,

Parallel-Group, Phase 4 Study to Evaluate the Efficacy and

Safety of Qudexy® XR in the Prevention of Migraine in Children 6 to 11 Years of Age.

For more information please contact:

Allyssa Sawyer at (813) 396-2736

19379A-Rejoin

(Currently Enrolling)

Long term, open label (dose blinded), extension study of eptinezumab in children and adolescents with chronic or episodic migraine.

For more information please contact:

Allyssa Sawyer at (813) 396-2736

19357A- Prospect 1

(Currently Enrolling)

Interventional, randomized, double-blind, parallel-group,

placebo-controlled study to evaluate the efficacy and safety of

intravenous (IV) eptinezumab in pediatric patients (6 to

17 years) for the preventive treatment of episodic migraine.

For more information please contact:

Allyssa Sawyer at (813) 396-2736

19356A- Prospect 2

(Currently Enrolling)

Interventional, randomized, double-blind, parallel-group,

placebo-controlled study to evaluate the efficacy and safety of IV

eptinezumab in adolescents (12-17 years) for the preventive treatment of chronic migraine.

For more information please contact:

Allyssa Sawyer at (813) 396-2736

CLIN-52120-463

C-BEOND

A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants.

For more information please contact:

Allyssa Sawyer at (813)396-2736

Enroll HD

Currently Enrolling

Enroll HD is an observational study for families effected by Huntington’s Disease. This study monitors how the disease materializes and changes over time in different individuals. This study is open to people with HD, as well as, those who are at-risk. The Enroll HD study is intended to speed up discoveries and develop new therapies for Huntington’s Disease.

For more information on this study please visit the Enroll-HD’s website at: www.enroll-hd.org

To enroll in this study or if you have any questions please contact Ruth Cajuste at 813-396-2155 or Kelly Elliot at 813-974-6022

Invest HD

Currently Enrolling 

A Randomized, Placebo-controlled, Double-blind Phase 3 Study to Evaluate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease. The purpose is to assess safety and tolerability of votoplam and to determine whether votoplam slows disease progression in patients with early symptomatic Huntington's disease (HD) compared to the control arm.

For more information please visit here.

To enroll in this study or if you have any questions please contact Ruth Cajuste at 813-396-2155.

BALANCE-MSS1

Currently enrolling

This is a phase 2, randomized, double-Blind, four-arm, placebo-controlled, multicenter study assessing the efficacy, safety and tolerability of three doses of orally administered BMS-986368, a FAAH/MAGL Inhibitor, for the treatment of spasticity in participants with multiple sclerosis.

For more information please visit here.

To enroll in this study please contact Amber McPherson at (813) 974-9423

ENHANCE

Currently enrolling

This is an open-label trial evaluating the efficacy when transitioning from current anti-CD20 therapy to ublituxumab.

For more information please visit here.

To enroll in this study please contact Amber McPherson at (813) 974-9423

IM047-050

Currently enrolling 

This phase 3 double-blind study is evaluating the efficacy and safety of oral ozanimod compared to oral fingolimod in children and adolescents with relapsing remitting Multiple Sclerosis

For more information please visit here. 

To enroll in this study please contact Amber McPherson at (813) 974-9423

Monarch

Currently enrolling

This is phase 3, randomized, double-blind, efficacy and safety study comparing orelabrutinib to placebo in patients with non-active secondary progressive multiple sclerosis.

For more information please visit here.

 To enroll in this study please contact Amber McPherson at (813) 974-9423

OCTAVIBE

Enrolling soon!  

This phase 3, open-label, single-arm, multi-center study will evaluate the safety and use of an on-body delivery system for the subcutaneous administration of ocrelizumab in patients with multiple sclerosis

For more information please visit here.

To enroll in this study please contact Amber McPherson at (813) 974-9423

POLARIS

Enrolling soon!                                          

This multicenter, randomized, double-Blinded, placebo-controlled, phase 2 trial will evaluate the efficacy, safety, and tolerability of subcontaneous efgartigimod ph20 in adult and adolescent aarticipants with autoimmune encephalitis

For more information please visit here.

To enroll in this study please contact Amber McPherson at (813) 974-9423

PRIMROSE

Currently enrolling                                             

 This is phase 3, randomized, double-blind, efficacy and safety study comparing orelabrutinib to placebo in patients with primary progressive multiple sclerosis

 For more information please visit here.

 To enroll in this study please contact Amber McPherson at (813) 974-9423

REMASTER

Currently Enrolling                                             

 This is A randomized, double-blind, placebo-controlled Phase III study to evaluate the efficacy and safety of remibrutinib in patients with secondary progressive multiple sclerosis

 For more information please visit here.

 To enroll in this study please contact Amber McPherson at (813) 974-9423

RESHAPE

Currently enrolling                                            

This is a randomized, open-label, parallel-group, non-inferiority study comparing efficacy, safety, and tolerability of remibrutinib after switching from ocrelizumab in participants living with relapsing multiple sclerosis, followed by open-label treatment with remibrutinib

For more information please visit here.

To enroll in this study please contact Amber McPherson at (813) 974-9423

SPHERE

Currently enrolling                                             

This registry aims to study the natural history of patients with neuromyelitis optica spectrum disorder(NMOSD), real-world effectivenss and safety of approved and off-label medications used in treatment of NMOSD and drug utlization treatment patterns

For more information please visit here.

To enroll in this study please contact Amber McPherson at (813) 974-9423

Sun-627-MS202

Currently enrolling

This is phase 2a, randomized, placebo-controlled clinical trial is evaluating the safety and tolerability of SUN-627 in participants with non-active secondary progressive and primary progressive multiple sclerosis (SPMS/​PPMS).

For more information please visit here. 

To enroll in this study please contact Amber McPherson at (813) 974-9423

Voyage

Currently enrolling

This is a phase 3 Study with an open-label extension in pediatric participants that will evaluate the safety, efficacy, and pharmacokinetics of diroximel fumarate and dimethyl fumarate

For more information please visit here.

To enroll in this study please contact Amber McPherson at (813) 974-9423

Myasthenia Gravis studies

Updated April 2026

Arcellx ARC-311 

- Currently Enrolling

For more information, please visit: NCT06626919

Janssen Pediatric MG (VIBRANCE)

-Currently Enrolling

For more information, please visit:    

NCT05265273

https://globaltrialfinder.janssen.com/trial/CR109137

MS700568_0183_ (MyClad)

-Currently Enrolling

For more information, please visit:

NCT06463587

NMD670-02-0002 (SYNAPSE-MG)

-Currently Enrolling

For more information, please visit:

NCT06414954

 ARGX-999-2-MG-2000 (ADAPT FORWARD)

-Currently Enrolling

For more information, please visit:

RC18G006 (UPSTREAM MG)

- Enrolling now! 

IMVT-1402-3101 (PROPEL) 

- Enrolling now! 

Neuropathy Studies - includes Multifocal Motor Neuropathy (MMN) and Chronic inflammatory demyelinating neuropathy (CIDP)

Updated April 2026

DNTH103-MMN-201 (MoMeNtum)

-Currently Enrolling

For more information, please visit:

NCT06537999

Myotonic Dystrophy type 1 (DM1) Studies

Updated April 2026

Sanofi DFI17808 (BrAAVe)

-Enrolling NOW!

A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 50 Years of Age With Non-congenital Myotonic Dystrophy Type 1 (BrAAVe). 

For more information, please visit:  

NCT06844214

Spasticity studies

Updated July 2025

Efgartigimod for Stiff Person Syndrome (ESPS)

-Enrolling soon!

For more information, please visit:

NCT06528392

PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort (PPMI)

Brief summary:

The Parkinson Progression Marker Initiative (PPMI) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes, and imaging, biologic and genetic markers of Parkinson's disease (PD) progression in study participants with manifest PD, prodromal PD, and healthy controls. 

The overall goal of PPMI is to identify markers of disease progression for use in clinical trials of therapies to reduce progression of PD disability.

Status: Enrolling

For more information, please visit:

PPMI Clinical

For more information, please contact:

Anja Jankovic
(813) 396-2008

mcom-parkinsons@usf.edu

Catalpa

(IPSEN)

ID: NCT06937931

Brief summary: The purpose of this study is to evaluate the efficacy and safety of the study drug, IPN10200, and to assess how well it works when compared with placebo in treating Cervical Dystonia (CD) in adults.

Status: Enrolling

For more information, please visit

Catalpa

For more information, please contact:

Anja Jankovic
(813) 396-2008

mcom-parkinsons@usf.edu

Bluerock

ID: NCT06944522

Brief Summary: Study BRT-DA01-301 is a Phase 3 multicenter, randomized, sham surgery-controlled, double-blind study to assess the efficacy and safety of bemdaneprocel in approximately 102 adults with Parkinson's Disease (PD).

Status: Enrolling

For more information, please visit:

Bluerock

For more information, please contact:

Anja Jankovic
(813) 396-2008

mcom-parkinsons@usf.edu 

Annovis

(A study of Buntanetap in participants with PD)

ID: NCT07284784

Brief Summary: This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study. This study will be conducted with two cohorts. Cohort 1 will enroll via invitation only for PD participants who have previously participated in buntanetap clinical trials. Cohort 2 will be for PD participants who are receiving deep brain stimulation (DBS) treatment. Qualified participants will receive buntanetap 30mg QD after a screening period of up to 42 days.

Status: DBS Enrolling

For more information, please visit:

Annovis

For more information, please contact:

Anja Jankovic
(813) 396-2008

mcom-parkinsons@usf.edu 

Neulark

Summary: A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease (NEULARK)

Status: Enrolling

For more information, please visit:  

Neulark

For more information, please contact:

Anja Jankovic
(813) 396-2008

mcom-parkinsons@usf.edu 

Paraiso

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease (PARAISO)

ID: NCT07174310

Brief Summary: The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of prasinezumab compared with placebo in participants with early-stage Parkinson's disease (PD) on stable symptomatic monotherapy with levodopa.

Status: Ongoing - closed to enrollment

For more information, please visit:

Paraiso

For more information, please contact:

Anja Jankovic
(813) 396-2008

mcom-parkinsons@usf.edu 

Abbvie Rossini

Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's Disease (ROSSINI)

ID: NCT06107426

Brief Summary: Parkinson's disease (PD) is a neurological condition that affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement. The purpose of this study is to evaluate how effective ABBV-951 is in treating adult participants with advanced PD in a real-world setting.

Status: Ongoing - closed to enrollment

For more information, please visit:

Abbvie Rossini

For more information, please contact:

Anja Jankovic
(813) 396-2008

mcom-parkinsons@usf.edu 

IPX 203-401-23

(ELEVATE-PD

ID: NCT06765668

Brief Summary: The primary purpose of this study is to evaluate the efficacy and safety of CREXONT under real-world conditions in participants with Parkinson's disease (PD).

Status: Ongoing - closed to enrollment

For more information, please visit: 

IPX 203-401-23

For more information, please contact:

Anja Jankovic
(813) 396-2008

mcom-parkinsons@usf.edu 

Padova

ID: NCT04777331

Brief Description: This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with Early Parkinson's Disease (PD) who are on stable symptomatic PD medication.

Status: Ongoing - closed to enrollment

For more information, please visit:

Padova

For more information, please contact:

Anja Jankovic
(813) 396-2008

mcom-parkinsons@usf.edu 

Pasadena

ID: NCT03100149

Brief summary: This multicenter, randomized, double-blind, placebo-controlled, Phase 2 study will evaluate the efficacy of intravenous prasinezumab (RO7046015/PRX002) versus placebo over 52 weeks in participants with early Parkinson's Disease (PD) who are untreated or treated with monoamine oxidase B (MAO-B) inhibitors since baseline. 

Status: Ongoing - closed to enrollment

For more information, please visit

Pasadena

For more information, please contact:

Anja Jankovic
(813) 396-2008

mcom-parkinsons@usf.edu 

TEVA

ID: NCT06568237

Brief summary: A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study (TOPAS-MSA)

Status: Ongoing - closed to enrollment

For more information, please visit:

TEVA

For more information, please contact:

Anja Jankovic
(813) 396-2008

mcom-parkinsons@usf.edu

ARCADIA

Currently Enrolling

For more information on this study please visit this website: https://clinicaltrials.gov/ct2/show/NCT03192215

To enroll in this study at USF please contact Tara McTigue at (813)259-0826

 BMS CV010 Factor IX inhibitor

Currently Enrolling

 MOST

Currently Enrolling

 CHARM

Currently Enrolling

 Pisces (Stem cells) 

Currently Enrolling

TCSD-S 

Currently Enrolling 

 Sleep SMART 

Currently Enrolling

ASPIRE

Currently Enrolling